84 Results for "

small intestinal

" in MedChemExpress (MCE) Product Catalog:
Products (84)

84 Results for "small intestinal" in MCE Product Catalog:

73
73 Publications Verification
Cat. No.: HY-16569
CAS No.: 64-86-8
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-B0113
CAS No.: 73590-58-6
Synonyms: H 16868
Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-B0113A
CAS No.: 95510-70-6
Synonyms: H 16868 sodium
Omeprazole (H 16868) sodium is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B1190
CAS No.: 50370-12-2
Synonyms: BL-S 578
Target:  

Bacterial Antibiotic EAAT

Research Areas:  

Infection Neurological Disease

Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-B1190A
CAS No.: 66592-87-8
Synonyms: BL-S 578 hydrate
Target:  

Bacterial Antibiotic EAAT

Research Areas:  

Infection Neurological Disease

Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil hydrate is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-114299
CAS No.: 203787-91-1
Purity:  99.94%
Synonyms: SNAC
Research Areas:  

Others

Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-12640
CAS No.: 22204-24-6
Purity:  99.97%
Synonyms: Pyrantel embonate
Target:  

Parasite nAChR

Research Areas:  

Infection

Pyrantel pamoate is an orally active antiparasitic agent. Pyrantel pamoate induces spastic paralysis in parasites via actions on neural and muscular cholinergic receptors as a nicotinic acetylcholine receptor (nAChR) agonist. Pyrantel pamoate eliminates both immature and mature endoparasites in horses. Pyrantel pamoate can be used in research related to parasitic infections .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-112484
CAS No.: 878451-87-7
Purity:  99.52%
Target:  

Organoid

Research Areas:  

Cancer

RS-246204 is a R-spondin-1 substitute compound that is able initiate small intestinal organoids without the use of the R-spondin-1 protein.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P2221
CAS No.: 914009-86-2
Synonyms: ZP1848
Target:  

GCGR

Research Areas:  

Inflammation/Immunology

Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1108A
Target:  

CRFR

Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1108
CAS No.: 681260-70-8
Target:  

CRFR

Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P2221B
Synonyms: ZP1848 acetate
Target:  

GCGR

Research Areas:  

Inflammation/Immunology

Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-B0113S
CAS No.: 922731-01-9
Synonyms: H 16868-d3
Omeprazole-d3 (H 16868-d3) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-12641
CAS No.: 33401-94-4
Purity:  98.69%
Target:  

Parasite nAChR

Research Areas:  

Infection

Pyrantel tartrate is an orally active antiparasitic agent. Pyrantel tartrate induces spastic paralysis in parasites via actions on neural and muscular cholinergic receptors as a nicotinic acetylcholine receptor (nAChR) agonist. Pyrantel tartrate eliminates both immature and mature endoparasites in horses. Pyrantel tartrate can be used in research related to parasitic infections .
loading...
    loading...
Cat. No.: HY-D1736
CAS No.: 158757-82-5
BODIPY FL-C16 is a BODIPY-labeled analog of Palmitic acid (HY-N0830), which serves as a fluorescent lipid tracer. BODIPY FL-C16 also acts as a ligand for liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) , with Kd values of 270 nM and 330 nM, respectively. BODIPY FL-C16 is rapidly taken up by cells, and after metabolic conversion to phospholipids, it is incorporated into the membrane structures of intracellular organelles and extracellular vesicles .
loading...
    loading...
Cat. No.: HY-W008491
CAS No.: 22423-26-3
Target:  

Phosphorylase

Research Areas:  

Inflammation/Immunology Cancer

TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC50 of 12.5 μM and human small intestinal UPase with an IC50 of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis .
loading...
    loading...
Cat. No.: HY-111237
CAS No.: 87414-49-1
Purity:  99.80%
Synonyms: Olomoucin
Butyrolactone I is an orally active and ATP-competitive inhibitor of CDK1. Butyrolactone I inhibits NF-κB, cdc2 kinase, Bax, ROS production, modulates the PERK/CHOP. Butyrolactone I mitigates heat-stress-induced Apoptosis. Butyrolactone I shows anti-inflammatory and intestinal protective activity. Butyrolactone I has antitumor effects against non-small cell lung, small cell lung, prostate cancer and leukemia. Butyrolactone I can be used in NASH research .
loading...
    loading...
Cat. No.: HY-P5005
CAS No.: 125093-93-8
Target:  

CMV PD-1/PD-L1

VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .
loading...
    loading...
Cat. No.: HY-106449
CAS No.: 203191-10-0
Purity:  ≥98.0%
Synonyms: DA-6034 free acid
Recoflavone (DA-6034 (free acid)), a synthetic derivative of the flavonoid Eupatilin (HY-N0783), is orally active. Recoflavone can inhibit the NF-κB pathway and induce [Ca( 2+)]i increase in epithelial cells. Recoflavone exhibits activities such as anti-inflammation, anti-tumor effects, protection of gastric and intestinal mucosa, and promotion of secretion in the ocular surface and salivary glands. Recoflavone can be used for the research of diseases such as dry eye, gastric injury, and intestinal injury .
loading...
    loading...
Cat. No.: HY-P990940
CAS No.: 2883118-92-9
Synonyms: MBE-748; M-9140 Antibody; MBE-2882 Antibody

Research Areas:  

Cancer

Precemtabart is a humanized IgG1 antibody targeting CEACAM5, with selectivity for CEACAM5-positive cells. Precemtabart binds to CEACAM5 on tumor cells to deliver the topoisomerase 1 inhibitor Exatecan (HY-13631), and induces cell death by inhibiting the function of TOP1. Precemtabart inhibits the growth of CEACAM5-positive cancer cells. Precemtabart causes dose-dependent hematolymphoid and intestinal-related effects in cynomolgus monkeys. Precemtabart can be used in research related to metastatic colorectal cancer, metastatic pancreatic ductal carcinoma, advanced gastric cancer, advanced non-small cell lung cancer, and advanced pancreatic adenocarcinoma .
loading...
    loading...